The recent review by the FDA panel regarding the risks and efficacy of selective serotonin reuptake inhibitors (SSRIs) in pregnant patients underscores a critical intersection of mental health treatment and maternal-fetal medicine. SSRIs, commonly prescribed for depression and anxiety disorders, have been a subject of concern due to their potential impact on pregnancy outcomes. This panel's evaluation aims to provide clearer guidelines for healthcare providers navigating the complexities of prescribing these medications during pregnancy.
MD, MPH, opened the session by acknowledging that “nearly 1 in 4 middle-aged women are on an antidepressant, and up to 5% of women in pregnancy are on an antidepressant.” While recognizing the potential benefit of SSRIs, he cautioned that the broader picture of mental health in the United States has not improved despite increasing prescriptions. “The more antidepressants we prescribe, the more depression there is,” he said, adding, “We have to start talking about root causes.”
faculty of Pharmacy, and CHU Ste-Justine in Montreal, and adjunct professor at the Faculty of Medicine, Université Claude Bernard, stated that depression and anxiety in pregnancy are prevalent and require treatment. “Untreated depression and anxiety during pregnancy has been shown to be associated with an increased risk of postpartum depression,” she said. She emphasized the complexity of risk-benefit analysis for antidepressant use in pregnancy and noted that the absolute risk of outcomes such as miscarriage or autism remains low, even if relative risk appears elevated in some studies.
A spokesperson for the FDA said in a statement that the claim that the panel was one-sided was “insulting to the independent scientists, clinicians, and researchers who dedicate their expertise to these panels.” The spokesperson added that FDA Commissioner Martin Makary “has an interest in ensuring policies reflect the latest gold standard science and protect public health.”
Health and Human Services Secretary Robert F. Kennedy Jr. has called for a probe into the risks of antidepressants. His “Make America Healthy Again” report in May claimed there were “potentially major long-term repercussions” associated with use of the drugs in childhood.
The panel discussion focused on a class of antidepressants known as selective serotonin reuptake inhibitors, or SSRIs, which includes Lexapro, Prozac and Zoloft. The medications increase levels of serotonin, a chemical messenger in the brain that can improve mood.
Experts in psychiatry often advocate for the continuation of SSRI treatment during pregnancy due to the significant risks associated with untreated mental illness. Untreated depression can exacerbate maternal health issues and negatively impact fetal development . The panel's focus on potential medication risks without adequately addressing these factors has raised concerns about misinformation and a lack of consensus within the medical community regarding best practices for managing perinatal mood disorders.
Read more
Johnson Delays House Vote on Epstein Files Until September Bangladesh Air Force Plane Crash Claims 27 Lives
Sara H
Also on site :
- Woman says ‘creepy’ delivery drivers would hang out in her parking lot. So she had to get creative: ‘Since doing that my deliveries come correctly’
- ‘This is devastating’: New Jersey dietician buys Siete gluten-free tortillas. Then she takes a taste—and says Pepsi is to blame
- Kevin Costner facing $400,000 lawsuit after Horizon 2 delay